Clinical Trial

Effect of Subconjunctival 5-fluorouracil on the Outcome of Ahmed Valve in Neovascular Glaucoma

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 6, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Neovascular glaucoma is a common and severe type of secondary closed-angle glaucoma. Topical treatments have variable effects and unfortunately often require surgery to control IOP. Although Glaucoma Drainage Device (GDD) such as Ahmed Glaucoma Valve (AGV) are a surgical choice in these patients, their effectiveness decreases over time. One of the main causes of failure in AGV surgery is the formation of scar tissue and fibrosis around the shunt plate. So, the aim of this study was to evaluate the effect of using MMC Intraoperative and 5FU Postoperative with AGV surgery in neovascular glaucoma patients according to a specific protocol, on the incidence of Hypertensive Phase (HP) and surgical success rate.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-03-30; most recent amendment 2025-05-01.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-05-01
Trial Details
NCT Number NCT05316142
Lead Sponsor Iran University of Medical Sciences
Conditions Neovascular Glaucoma
Enrollment 70 participants
Start Date 2024-05-01
Primary Completion 2025-12-01 (estimated)
Study Completion 2025-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-05-06